Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New Boston Scientific defibrillators receive CE Mark approval

Boston Scientific : 22 January, 2008  (New Product)
Boston Scientific has received CE Mark approval for the company’s Cognis cardiac resynchronisation therapy defibrillator (CRT-D) and Teligen implantable cardioverter defibrillator (ICD).
The devices are new platforms to treat heart failure and sudden cardiac death and are the result of a multi-year research and development effort to provide physicians enhanced clinical options for their patients.

When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features. The Cognis CRT-D and the Teligen ICD are designed to eliminate those compromises.

They are among the world's smallest and thinnest high-energy devices at 32.5cc and 31.5cc respectively, while less than 10mm thick. Both devices offer features based on engineering advances, including extended battery longevity, self-correcting software and improved programming technology. Both devices also offer SafetyCore, a feature that in the unlikely event of a system error provides lifesaving shock therapy and basic pacing functionality.

Key features of the Cognis CRT-D include:

- SmartDelay: quickly proposes programmable device settings, which enables physicians to tailor individualised pacing therapy for their patients.

- Bi-V Trigger: helps physicians manage heart failure patients with frequent atrial arrhythmias.

- Electronic Repositioning: provides physicians with six configurations for stimulating the left side of the heart even after implant, which may help avoid an additional surgical procedure.

Key features of the Teligen ICD include:

- Thinnest device available in the world, designed with patient comfort
in mind

- Reverse Mode Switch: designed to eliminate unnecessary ventricular pacing.

- Quick Convert: provides the ability for patients to receive pacing therapy for ventricular tachycardias.

'Our CRM team is refocused on delivering therapy systems that meet clinician needs for safety, reliability and better patient outcomes,' said Jim Tobin, president and chief executive officer of Boston Scientific. 'We have re-engineered the way we design, build, test and report on our technology. The Cognis CRT-D and the Teligen ICD are testaments to the revitalisation of our CRM business and are just two of the many new products we plan to launch in 2008.'

The first Cognis and Teligen implants are scheduled to take place early next month. The company plans to build to a full launch in Europe and other international markets in the second quarter.

The Cognis CRT-D and the Teligen ICD are pending approval by the US Food and Drug Administration and are not available for sale in the USA.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo